About This Trial
Individualized neoantigen therapy in combination with Keytruda for high-risk melanoma patients post-surgery.
Primary Endpoints
- Recurrence-free survival
- Overall survival
Latest Update
February 2026
Phase 2b results showed 44% reduction in recurrence/death risk vs Keytruda alone. FDA granted Breakthrough Therapy designation.
Lead Investigators
DJ
Dr. Jeffrey Weber Deputy Director, Perlmutter Cancer Center, NYU